StockNews.com Upgrades OPKO Health (NASDAQ:OPK) to Hold

OPKO Health (NASDAQ:OPK) was upgraded by equities researchers at StockNews.com from a “sell” rating to a “hold” rating in a report issued on Monday.

OPK has been the topic of several other reports. HC Wainwright reissued a “buy” rating and issued a $3.00 price objective on shares of OPKO Health in a report on Monday. Barrington Research reissued an “outperform” rating and issued a $2.25 price target on shares of OPKO Health in a report on Friday.

OPKO Health Stock Performance

NASDAQ OPK traded up $0.01 during mid-day trading on Monday, reaching $1.75. 29,653,360 shares of the stock were exchanged, compared to its average volume of 4,457,309. OPKO Health has a 1 year low of $0.86 and a 1 year high of $1.84. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97. The business’s 50 day moving average is $1.55 and its 200-day moving average is $1.55. The company has a market capitalization of $1.19 billion, a P/E ratio of -9.21 and a beta of 1.63.

OPKO Health (NASDAQ:OPK) last posted its earnings results on Thursday, February 27th. The biotechnology company reported $0.01 EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.09. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. The firm had revenue of $183.60 million for the quarter, compared to analysts’ expectations of $155.42 million. On average, equities research analysts forecast that OPKO Health will post -0.25 EPS for the current fiscal year.

Insider Buying and Selling at OPKO Health

In other OPKO Health news, CEO Phillip Md Et Al Frost bought 150,000 shares of the stock in a transaction on Friday, January 17th. The shares were bought at an average price of $1.47 per share, with a total value of $220,500.00. Following the purchase, the chief executive officer now directly owns 213,186,477 shares in the company, valued at $313,384,121.19. This trade represents a 0.07 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders bought 1,389,971 shares of company stock valued at $2,124,442 over the last quarter. 47.26% of the stock is currently owned by insiders.

Hedge Funds Weigh In On OPKO Health

Several hedge funds and other institutional investors have recently modified their holdings of the business. FMR LLC raised its holdings in OPKO Health by 103.6% in the 3rd quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 11,089 shares during the last quarter. Orion Portfolio Solutions LLC purchased a new stake in shares of OPKO Health in the third quarter valued at approximately $45,000. Cibc World Markets Corp acquired a new stake in shares of OPKO Health in the fourth quarter valued at approximately $45,000. Zacks Investment Management purchased a new position in OPKO Health during the fourth quarter worth approximately $49,000. Finally, Ieq Capital LLC purchased a new position in OPKO Health during the fourth quarter worth approximately $52,000. 64.63% of the stock is owned by hedge funds and other institutional investors.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.